2015
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. The Journal Of Clinical Psychiatry 2015, 76: 1075-84. PMID: 26214725, PMCID: PMC4560666, DOI: 10.4088/jcp.14m09123.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialObsessive-compulsive disorderSmall open-label trialsTreatment-refractory obsessive-compulsive disorderGlutamate modulator riluzoleSignificant residual symptomsOpen-label trialSubset of patientsDSM-IV obsessive-compulsive disorderBest available treatmentsPlacebo leadRiluzole groupRefractory symptomsPartial responseSignificant morbidityResidual symptomsModerate nauseaAvailable treatmentsStandard interventionGlutamate homeostasisRiluzoleSide effectsSRI treatmentPatientsSecondary analysis
2013
Meta-analysis: pharmacological treatment of pathological gambling
Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Review Of Neurotherapeutics 2013, 13: 887-894. PMID: 23952195, DOI: 10.1586/14737175.2013.814938.Peer-Reviewed Original ResearchConceptsStandardized mean differenceReported efficacyPharmacological treatmentOpiate antagonistPathological gamblingPlacebo-controlled trialBenefits of medicationsCurrent trial dataFixed-effects modelTreat principleNon-significant effect sizeITT principlePharmacological agentsMeta-AnalysisTrial dataPublication biasSecondary analysisPlaceboMean differenceAntagonistTrialsMedicationsEfficacyYear of publicationEffect sizeMeta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity
Qawasmi A, Landeros-Weisenberger A, Bloch MH. Meta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity. Pediatrics 2013, 131: e262-e272. PMID: 23248232, PMCID: PMC3529943, DOI: 10.1542/peds.2012-0517.Peer-Reviewed Original ResearchConceptsInfant visual acuityMonths of ageLCPUFA supplementationVisual acuityInfant formulaTrial methodologic qualitySecondary subgroup analysisVisual acuity developmentVisual resolution acuityPrimary outcomeSubgroup analysisMethodologic qualityUnsupplemented infantsAcuity developmentNineteen studiesCurrent evidenceAcuityResolution acuityBirth statusSecondary analysisPublication biasMean differenceInfantsSupplementationSignificant heterogeneity
2012
Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition
Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH. Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition. Pediatrics 2012, 129: 1141-1149. PMID: 22641753, PMCID: PMC3362904, DOI: 10.1542/peds.2011-2127.Peer-Reviewed Original ResearchConceptsLCPUFA supplementationClinical trialsInfant formulaLong-Chain Polyunsaturated Fatty Acid SupplementationBayley ScalesPolyunsaturated Fatty Acid SupplementationTrial methodologic qualityInfants fed formulaWeighted mean differenceSecondary subgroup analysisFatty acid supplementationMeasures of neurodevelopmentInfant Development scoresFed formulaPrimary outcomeSubgroup analysisUnsupplemented formulaMethodologic qualityInclusion criteriaPrematurity statusAcid supplementationSupplementation efficacySecondary analysisPublication biasMean differencePharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. Pediatrics 2012, 129: e1301-e1310. PMID: 22529279, PMCID: PMC3340598, DOI: 10.1542/peds.2011-3285.Peer-Reviewed Original ResearchConceptsSerotonin receptor inhibitorsPublication biasTrial resultsPlacebo-controlled trialAutism spectrum disorderRepetitive behaviorsAvailable medicationsPatient agePharmacologic treatmentPrimary outcomeUnpublished trialsEgger's testReceptor inhibitorsMean improvementSpectrum disorderFunnel plotTrial designSecondary analysisTrial durationRating ScaleEfficacyTrialsTweedie's trimMedicationsTreatment
2011
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry 2011, 17: 1272-1282. PMID: 21931319, PMCID: PMC3625950, DOI: 10.1038/mp.2011.100.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialMajor depressive disorderBaseline depression severityDepression severityPublication biasMethodological qualityGreater baseline depression severityDocosahexaenoic acidEicosapentaenoic acidTrial methodological qualityPrimary outcome measureNon-significant benefitTreatment of depressionLow methodological qualityFatty acid treatmentTreat analysisDepressive disorderMajor depressionSources of heterogeneityOutcome measuresClinical measuresTreatment efficacySystematic reviewSecondary analysisStudy participants